DAYQUIL SINEX OTC
Generic Name and Formulations:
Acetaminophen 325mg, phenylephrine HCl 5mg; per LiquiCap.
Procter & Gamble Pharmaceuticals
Indications for DAYQUIL SINEX:
Sinus pain, congestion, headache.
2 caps every 4 hours; max 6 doses/24 hours.
<4yrs: not recommended. 4–12yrs: consult a doctor.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Thyroid disease. Diabetes. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day. β-blockers increase pressor effects of sympathomimetics. Antagonizes antihypertensives.
Analgesic + sympathomimetic.
Nervousness, dizziness, insomnia, hepatotoxicty (overdosage).
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|